Ritu Baral
Stock Analyst at TD Cowen
(3.02)
# 1,271
Out of 5,154 analysts
45
Total ratings
40%
Success rate
3.85%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ritu Baral
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $35 → $37 | $22.40 | +65.18% | 3 | Feb 26, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $202 → $306 | $260.33 | +17.54% | 1 | Jan 9, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $67 | $37.22 | +80.01% | 1 | Jan 5, 2026 | |
| INSM Insmed | Maintains: Buy | $269 → $241 | $143.57 | +67.86% | 7 | Dec 18, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $97 → $133 | $134.95 | -1.44% | 3 | Dec 16, 2025 | |
| MIST Milestone Pharmaceuticals | Upgrades: Buy | $8 | $1.59 | +403.14% | 1 | Dec 15, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $251 → $353 | $310.58 | +13.66% | 1 | Dec 8, 2025 | |
| VERA Vera Therapeutics | Maintains: Buy | $60 → $73 | $38.85 | +87.90% | 2 | Dec 5, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $390 → $554 | $439.34 | +26.10% | 2 | Aug 26, 2025 | |
| SPRO Spero Therapeutics | Downgrades: Hold | n/a | $2.29 | - | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.71 | - | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $282 → $371 | $320.51 | +15.75% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.45 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $175 | $16.23 | +978.25% | 1 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $53.78 | - | 2 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.80 | - | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $15.17 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.54 | - | 2 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $42.00 | - | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.29 | - | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.39 | - | 2 | Jul 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $570.49 | - | 2 | Jan 12, 2018 |
ACADIA Pharmaceuticals
Feb 26, 2026
Maintains: Buy
Price Target: $35 → $37
Current: $22.40
Upside: +65.18%
Krystal Biotech
Jan 9, 2026
Maintains: Buy
Price Target: $202 → $306
Current: $260.33
Upside: +17.54%
vTv Therapeutics
Jan 5, 2026
Initiates: Buy
Price Target: $67
Current: $37.22
Upside: +80.01%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $269 → $241
Current: $143.57
Upside: +67.86%
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $97 → $133
Current: $134.95
Upside: -1.44%
Milestone Pharmaceuticals
Dec 15, 2025
Upgrades: Buy
Price Target: $8
Current: $1.59
Upside: +403.14%
Praxis Precision Medicines
Dec 8, 2025
Maintains: Buy
Price Target: $251 → $353
Current: $310.58
Upside: +13.66%
Vera Therapeutics
Dec 5, 2025
Maintains: Buy
Price Target: $60 → $73
Current: $38.85
Upside: +87.90%
Madrigal Pharmaceuticals
Aug 26, 2025
Maintains: Buy
Price Target: $390 → $554
Current: $439.34
Upside: +26.10%
Spero Therapeutics
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.29
Upside: -
Nov 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.71
Upside: -
Oct 21, 2024
Maintains: Buy
Price Target: $282 → $371
Current: $320.51
Upside: +15.75%
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $5.45
Upside: -
Mar 22, 2023
Maintains: Outperform
Price Target: $125 → $175
Current: $16.23
Upside: +978.25%
Nov 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $53.78
Upside: -
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.80
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $15.17
Upside: -
Jul 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.54
Upside: -
Mar 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $42.00
Upside: -
Jun 29, 2020
Initiates: Outperform
Price Target: n/a
Current: $1.29
Upside: -
Jul 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $0.39
Upside: -
Jan 12, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $570.49
Upside: -